These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28397352)

  • 1. Effects of expanding the look-back period to all available data in the assessment of covariates.
    Nakasian SS; Rassen JA; Franklin JM
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):890-899. PubMed ID: 28397352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods.
    Connolly JG; Schneeweiss S; Glynn RJ; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):665-670. PubMed ID: 30786103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correcting hazard ratio estimates for outcome misclassification using multiple imputation with internal validation data.
    Ni J; Leong A; Dasgupta K; Rahme E
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):925-934. PubMed ID: 28503870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates.
    Brunelli SM; Gagne JJ; Huybrechts KF; Wang SV; Patrick AR; Rothman KJ; Seeger JD
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):542-50. PubMed ID: 23526818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders.
    Gilbertson DT; Bradbury BD; Wetmore JB; Weinhandl ED; Monda KL; Liu J; Brookhart MA; Gustafson SK; Roberts T; Collins AJ; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):269-77. PubMed ID: 26608680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.
    Schneeweiss S; Rassen JA; Glynn RJ; Avorn J; Mogun H; Brookhart MA
    Epidemiology; 2009 Jul; 20(4):512-22. PubMed ID: 19487948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated Claims Data.
    Ripollone JE; Huybrechts KF; Rothman KJ; Ferguson RE; Franklin JM
    Am J Epidemiol; 2020 Jun; 189(6):613-622. PubMed ID: 31845719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality.
    Dore DD; Liang C; Ziyadeh N; Norman H; Bayliss M; Seeger JD
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():29-36. PubMed ID: 22552977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An application of propensity score matching using claims data.
    Seeger JD; Williams PL; Walker AM
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):465-76. PubMed ID: 15651087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The missing cause approach to unmeasured confounding in pharmacoepidemiology.
    Abrahamowicz M; Bjerre LM; Beauchamp ME; LeLorier J; Burne R
    Stat Med; 2016 Mar; 35(7):1001-16. PubMed ID: 26932124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classifying medical histories in US Medicare beneficiaries using fixed vs all-available look-back approaches.
    Conover MM; Stürmer T; Poole C; Glynn RJ; Simpson RJ; Pate V; Jonsson Funk M
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):771-780. PubMed ID: 29655187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short look-back periods in pharmacoepidemiologic studies of new users of antibiotics and asthma medications introduce severe misclassification.
    Riis AH; Johansen MB; Jacobsen JB; Brookhart MA; Stürmer T; Støvring H
    Pharmacoepidemiol Drug Saf; 2015 May; 24(5):478-85. PubMed ID: 25601142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of propensity score technique to account for exposure-related covariates: an example and lesson.
    Seeger JD; Kurth T; Walker AM
    Med Care; 2007 Oct; 45(10 Supl 2):S143-8. PubMed ID: 17909373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-to-many propensity score matching in cohort studies.
    Rassen JA; Shelat AA; Myers J; Glynn RJ; Rothman KJ; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():69-80. PubMed ID: 22552982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments.
    Patorno E; Glynn RJ; Hernández-Díaz S; Liu J; Schneeweiss S
    Epidemiology; 2014 Mar; 25(2):268-78. PubMed ID: 24487209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using prescription claims data for drugs available over-the-counter (OTC).
    Yood MU; Campbell UB; Rothman KJ; Jick SS; Lang J; Wells KE; Jick H; Johnson CC
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):961-8. PubMed ID: 17654746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics.
    Toh S; García Rodríguez LA; Hernán MA
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2(0 2):13-20. PubMed ID: 22552975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data.
    Meid AD; Heider D; Adler JB; Quinzler R; Brenner H; Günster C; König HH; Haefeli WE
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1434-1442. PubMed ID: 27633276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a propensity score to adjust for channelling bias with NSAIDs.
    Morant SV; Pettitt D; MacDonald TM; Burke TA; Goldstein JL
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):345-53. PubMed ID: 15170763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of entropy balance and probability weighting methods to generalize observational cohorts to a population: a simulation and empirical example.
    Harvey RA; Hayden JD; Kamble PS; Bouchard JR; Huang JC
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):368-377. PubMed ID: 27859943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.